Published in Assay Drug Dev Technol on June 01, 2010
Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One (2010) 1.36
Immune monitoring technology primer: Single Cell Network Profiling (SCNP). J Immunother Cancer (2015) 0.77
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway. Pharmaceuticals (Basel) (2010) 0.75
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res (2010) 1.73
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol (2006) 1.68
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One (2010) 1.36
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol (2006) 1.35
Active learning with support vector machines in the drug discovery process. J Chem Inf Comput Sci (2003) 1.31
Performance of 3D-database molecular docking studies into homology models. J Med Chem (2004) 1.23
Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol (2012) 1.10
Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry B Clin Cytom (2012) 1.08
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS One (2010) 1.08
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res (2012) 0.96
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol (2013) 0.91
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med (2011) 0.90
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther (2006) 0.88
High-dimensional analysis of the aging immune system: verification of age-associated differences in immune signaling responses in healthy donors. J Transl Med (2014) 0.87
Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications. Best Pract Res Clin Haematol (2010) 0.87
Building predictive ADMET models for early decisions in drug discovery. Curr Opin Drug Discov Devel (2004) 0.85
Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. Cytometry B Clin Cytom (2013) 0.84
Racial differences in B cell receptor signaling pathway activation. J Transl Med (2012) 0.84
Evaluation of a novel shape-based computational filter for lead evolution: application to thrombin inhibitors. J Med Chem (2002) 0.82
Using ensembles to classify compounds for drug discovery. J Chem Inf Comput Sci (2003) 0.82
Patient-specific classifications of human malignant disease. Curr Opin Mol Ther (2009) 0.82
Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy (2007) 0.80
Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status. PLoS One (2013) 0.79
Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. Cytometry B Clin Cytom (2013) 0.78
Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease. Autoimmunity (2010) 0.78
Single cell network profiling assay in bladder cancer. Cytometry A (2013) 0.77
CD22-directed monoclonal antibody therapy for lymphoma. Semin Oncol (2003) 0.76
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One (2013) 0.76
Inter-donor variation in cell subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol (2012) 0.76
Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP). J Transl Med (2014) 0.75
Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. J Clin Oncol (2008) 0.75
Feature-map vectors: a new class of informative descriptors for computational drug discovery. J Comput Aided Mol Des (2007) 0.75